U.S., Oct. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07880769) titled 'Preclinical Type 1 Diabetes: the VIP-1 Study' on Oct. 12.
Brief Summary: Type 1 diabetes (T1D) is preceded by a presymptomatic phase featured by the presence of islet autoantibodies (aAbs) without (Stage 1) or with (Stage 2) dysglycemia. Clinical investigations targeting Stage 1 or Stage 2 disease have been using the time to clinical disease progression (Stage 3) as primary outcome, with a consequent need for relative high numerosity and prolonged follow-up.
Additional hurdles limit the feasibility of disease modifying therapy (DMT) trials for preclinical T1D, including the need for an established screening program able to identify...